Multiagent chemotherapy including IrIVA regimen and maintenance therapy in the treatment of desmoplastic small round cell tumor.
Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Child
Cyclophosphamide
/ administration & dosage
Dactinomycin
/ administration & dosage
Desmoplastic Small Round Cell Tumor
/ drug therapy
Dose-Response Relationship, Drug
Doxorubicin
/ administration & dosage
Humans
Ifosfamide
/ administration & dosage
Irinotecan
/ administration & dosage
Male
Treatment Outcome
Vincristine
/ administration & dosage
Vinorelbine
/ administration & dosage
Young Adult
Desmoplastic small round cell tumor
IrIVA
chemotherapy
irinotecan
maintenance therapy
vinorelbine
Journal
Tumori
ISSN: 2038-2529
Titre abrégé: Tumori
Pays: United States
ID NLM: 0111356
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
pubmed:
18
2
2021
medline:
19
2
2022
entrez:
17
2
2021
Statut:
ppublish
Résumé
This study reports the treatment feasibility and efficacy of a novel multiagent intensive treatment program for young patients with desmoplastic small round cell tumor. This small series includes three patients and should be seen as a first suggestion of integration of the dose density and the maintenance chemotherapy concept. The IrIVA regimen (irinotecan, ifosfamide, vincristine, and actinomycin-D) is added-used at a short interval between chemotherapy administrations-at more classic intensive ifosfamide-based regimens. The vinorelbine and low-dose oral cyclophosphamide maintenance therapy is added at the end of conventional chemotherapy to achieve an antiangiogenic effect.
Identifiants
pubmed: 33594944
doi: 10.1177/0300891621995250
doi:
Substances chimiques
Dactinomycin
1CC1JFE158
Vincristine
5J49Q6B70F
Irinotecan
7673326042
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Vinorelbine
Q6C979R91Y
Ifosfamide
UM20QQM95Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM